Mark Searcey

Sort by:

Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity.

Klaus Pors, Paul M. Loadman, +7 authors Laurence H. Patterson
Chemical communications
2011

The identification of an agent that is selectively activated by a cytochrome P450 (CYP) has the potential for tissue specific dose intensification as a means of significantly improving its… (More)

Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction

Richard J Steel, Jonathan Cowan, Estelle Payerne, Maria A O'Connell, Mark Searcey
ACS medicinal chemistry letters
2012

Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is increasingly recognized as a central regulator of multiple signaling pathways in inflammation and cancer, and the ability to use chemical… (More)

Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studies.

Simon Dawson, John P Malkinson, David Paumier, Mark Searcey
Natural product reports
2007

Echinomycin is the prototypical bisintercalator, a molecule that binds to DNA by inserting two planar chromophores between the base-pairs of duplex DNA, placing its cyclic depsipeptide backbone in… (More)

Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products.

Nandita Ghosh, Helen M Sheldrake, Mark Searcey, Klaus Pors
Current topics in medicinal chemistry
2009

CC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antibiotics that have been the subject of extensive investigations due to their mode of action and… (More)

Synthesis of distamycin A polyamides targeting G-quadruplex DNA.

Michael J B Moore, Francisco Cuenca, Mark Searcey, Stephen Neidle
Organic & biomolecular chemistry
2006

A number of amide-linked oligopyrroles based on distamycin molecules have been synthesized by solid-state methods, and their interactions with a human intramolecular G-quadruplex have been measured… (More)

Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions.

Alex Shaginian, Landon R. Whitby, +6 authors Dale L. Boger
Journal of the American Chemical Society
2009

The design and solution-phase synthesis of an alpha-helix mimetic library as an integral component of a small-molecule library targeting protein-protein interactions are described. The iterative… (More)

Ligand bridging of the DNA Holliday junction: molecular recognition of a stacked-X four-way junction by a small molecule.

Anna L. Brogden, Nicholas H. Hopcroft, Mark Searcey, Christine J Cardin
Angewandte Chemie
2007

Resistance in cancer: a target for drug discovery.

Mark Searcey, Laurence H. Patterson
Current medicinal chemistry. Anti-cancer agents
2004

Resistance remains a major problem in the clinical utility of cancer chemotherapy. However, it also represents a tumour cell phenotype that is in many ways different, and thus distinguishable, from… (More)

The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction.

Ryan C Clark, Sang Yeul Lee, Mark Searcey, Dale L. Boger
Natural product reports
2009

Inhibitors of key protein-protein interactions are emerging as exciting therapeutic targets for the treatment of cancer. One such interaction between MDM2 (HDM2) and p53, that silences the tumour… (More)

Identification and characterisation of a G-quadruplex forming sequence in the promoter region of nuclear factor (erythroid-derived 2)-like 2 (Nrf2).

Zoë Ann Ella Waller, Lesley Ann Howell, Colin J Macdonald, Maria A O'Connell, Mark Searcey
Biochemical and biophysical research…
2014

The transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) regulates multiple antioxidants, Phase II detoxification enzymes and other cytoprotective enzymes in cells. Activation of… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences